Fate therapeutics highlights cancer-selective, her2-targeting profile of ft825 / ono-8250 car t-cell product candidate for treatment of advanced solid tumors at 2024 sitc annual meeting

Novel h 2 casmab-2 antigen binding domain shown to preferentially target her2 expressed on tumor cells in preclinical studies

CAR Ratings Summary

CAR Quant Ranking